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Background: The last decade has seen a dramatic increase in international and domestic funding for malaria
control, coupled with important declines in malaria incidence and mortality in some regions of the world. As the
ongoing climate of financial uncertainty places strains on investment in global health, there is an increasing need
to audit the origin, recipients and geographical distribution of funding for malaria control relative to populations at
risk of the disease.
Methods: A comprehensive review of malaria control funding from international donors, bilateral sources and
national governments was undertaken to reconstruct total funding by country for each year 2006 to 2010. Regions
at risk from Plasmodium falciparum and/or Plasmodium vivax transmission were identified using global risk maps for
2010 and funding was assessed relative to populations at risk. Those nations with unequal funding relative to a
regional average were identified and potential explanations highlighted, such as differences in national policies,
government inaction or donor neglect.
Results: US$8.9 billion was disbursed for malaria control and elimination programmes over the study period. Africa
had the largest levels of funding per capita-at-risk, with most nations supported primarily by international aid.
Countries of the Americas, in contrast, were supported typically through national government funding.
Disbursements and government funding in Asia were far lower with a large variation in funding patterns. Nations
with relatively high and low levels of funding are discussed.
Conclusions: Global funding for malaria control is substantially less than required. Inequity in funding is
pronounced in some regions particularly when considering the distinct goals of malaria control and malaria
elimination. Efforts to sustain and increase international investment in malaria control should be informed by
evidence-based assessment of funding equity.
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vivaxBackground
Significant progress has been made towards achieving
the Millennium Development Goals [1,2], especially the
target for malaria set out in Goal 6.3 of halting and re-
versing the incidence of malaria by 2015 [3-6]. Success
has also been attained by national malaria elimination
programmes, with countries such as the United Arab
Emirates [7], Morocco [8] and Turkmenistan [9] certi-
fied as malaria free between 2007 and 2012. These
achievements have been driven by huge increases in the* Correspondence: david.pigott@zoo.ox.ac.uk; peter.gething@zoo.ox.ac.uk
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reproduction in any medium, provided the oravailability of funding for malaria control, and the last
decade has seen the increasing prominence of inter-
national donors in assisting national governments in
control strategies [10,11].
However, international donor support is at a critical
juncture. The ongoing global financial crisis and auster-
ity programmes promoted by many governments has
meant the trend of increasing international funding has
shown signs of significant slowdown [12]. Commitments
on future funding are becoming increasingly difficult to
secure, with the Global Fund to Fight AIDS, Tubercu-
losis and Malaria (Global Fund) forced to suspend new
projects until 2014 with US$500 million less fundingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Faltering funding will, inevitably, jeopardize the progress
of recent years in malaria control and raise the likeli-
hood of deteriorating morbidity and mortality trends
and the threat of resurgence in transmission [15-17]. In
an austere era, sustaining momentum in malaria control
requires that limited financial resources are deployed
with maximum efficiency, a sentiment emphasized in
the most recent Global Fund “Investing for Impact”
strategy [18,19]. Moving beyond slogans to achieve this
objective requires a comprehensive triangulation of (i)
existing funding on malaria control from all sources in
each endemic country, (ii) the relative contribution of
different national and international funders and (iii) the
level of funding relative to populations at risk.
Previous studies have assessed equity in malaria fi-
nancing on a global scale with a focus on investments
by international donors [20,21]. Whilst informative,
inferences on overall levels of equity are limited by
the omission of data on national government funding.
Apparent shortfalls in international assistance may be
explained by investment within wealthier nations with
adequate internal budgets of their own to support
control programmes. Conversely, apparently generous
international support to a country may still be inad-
equate when national governmental contributions to
disease control are low. Here, explicit measures of
both internal and external funding are incorporated to
provide, for the first time, a comprehensive audit of
combined malaria control financing. Levels of funding
are compared to revised population at risk figures, calcu-
lated using the latest 2010 transmission limits for both
Plasmodium falciparum [22] and Plasmodium vivax [23]
produced by the Malaria Atlas Project (MAP) [24,25].
This analysis has allowed us to compare levels of gov-
ernmental support to national control programmes as
well as identify those apparently neglected by inter-
national donor funding.
Methods
A review of malaria funding from international donors,
non-governmental organisations (NGOs) and govern-
ment budgets received by each malaria endemic country
was undertaken (Additional files 1 and 2). This funding
was standardized per capita-at-risk, using combined
P. falciparum and P. vivax transmission limits. Na-
tional funding was compared to a regional equity
level. Each of these components is now described in
more detail.
External funding disbursements
This study attempts to capture as broad a range of
funding sources as possible in order to best enumerate
the total monies available from external sources forcountries to invest in their malaria programmes. Previ-
ous studies assessed donor assistance via commitments,
whereas we have evaluated disbursements wherever
possible. The latter presents a more accurate represen-
tation of funding within the sector. In several cases,
committed funds have been withdrawn before being
completely disbursed (e.g. for political, logistical or
other reasons relating to improper use of funds or inef-
fective programmes) or disbursements have occurred
over a time period longer than initially anticipated [26].
Disbursements, therefore, allow for a more informed
judgement of funding equity to be made, since they best
cover the real monies received by each country. It is
assumed that all monies disbursed to a country are sub-
sequently spent on national malaria control and elimin-
ation programmes.
Detailed information on funding by country was
obtained from the following sources: The President’s Mal-
aria Initiative (PMI) up to and including the fiscal year
(FY) 2010; the Global Fund up to and including Round 10
grants (decided before December 2010); the Development
Assistance Committee (DAC), whose members provide
independent bilateral agreements, with data listed from
2005 to 2010; UNICEF (2005–2010); and the Booster Pro-
gram for Malaria Control in Africa (headed by the World
Bank) including Phase 1 funding schemes. The disbursed
amounts from the DAC and UNICEF were obtained from
the Creditor Reporting System (CRS) [27] using the search
criteria “12262: Malaria Control” as the Sector code, and
“Disbursements gross (current USD millions)” in the
Amount field. For PMI, funding was based upon the Fifth
Annual Report (for up to FY 2010) [28] and the Malaria
Operational Plans for 2011 [29], whilst Global Fund dis-
bursement data were obtained from the organisation’s
country portfolios [30]. World Bank data were collected
from the Booster Program grants listing [31], and were
assumed to be disbursed evenly across the entire grant
period. All currency rates were consistent to the year of
disbursement since this allowed for a better understanding
of the actual purchasing power these monies provided at
that time.
Only those grants that were specifically malaria focused
or had clearly defined malaria budgets within an overall
larger grant were selected. Although substantial sums are
provided for general health-system and infrastructure
strengthening and research into malaria, these cannot be
directly apportioned to malaria control. Many multilateral
grants were therefore excluded, such as those from the
Global Alliance for Vaccines and Immunisation (GAVI),
the World Bank, the Bill and Melinda Gates Foundation
and grants (including many research grants) where no
clear evidence of which countries were to benefit. As a re-
sult, the data here represent a lower bound estimate for
external support levels.
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two or more countries described in Additional file 3. In
order to gain national subtotals, these regional schemes
were divided using final and proposed budgets. Dis-
bursement ratios were assumed constant throughout
the grant period.
Government funding
Grant proposals to the Global Fund were collated [30],
using the most up to date information from 83 countries
to identify domestic budgets for government funding.
This approach was used because these proposals repre-
sent the most accessible yet detailed account of national
malaria budgets, and hence allowed us to avoid double-
counting of funding. It is assumed that such reports
represent a valid, accurate and unbiased assessment of
government budgets. For the 20 (21%) countries where
this was not possible (because no Global Fund support
had been requested) we used the World Malaria Report
2011 [32] as the next most reliable reference. If data
were missing for a specific year, we used the figures
from the adjacent years to make a reasoned estimate by
extrapolation. National funding on malaria therefore
can be represented by the sum of government budgets
and disbursed monies.
Gross domestic product
Gross Domestic Product (GDP) estimates for 2010 were
taken from the World Bank online data resource [33]
and divided by the national population, taken from the
UN population division. In cases where no 2010 data
were present, the 2009 figure was used, or if this was
absent, the CIA factbook [34].
Assessment of populations at risk
Using methods outlined elsewhere, absolute figures for
populations at risk of stable and unstable P. falciparum
[22] and P. vivax [23] transmission for 2010 were cal-
culated. Combined P. falciparum/P. vivax risk for a
given population was defined by the highest risk level
present for either P. falciparum or P. vivax (Table 1).
Whilst risk for P. falciparum affects the entire popula-
tion, P. vivax impacts only Duffy-positive individuals
[35,36]. Therefore, in locations where P. vivax was stable
and P. falciparum unstable (marked with * in Table 1) a
global map of predicted Duffy negativity prevalence [37]
was used to calculate the Duffy-negative populationTable 1 Criteria for evaluating population sizes at combined
Stable Pv Risk
Stable Pf Risk All Stable Risk
Unstable Pf Risk Duffy Dependent*
No Pf Risk Duffy Positives Stable Riskfraction at that location. This fraction was classified as
being at unstable risk and the remainder as being at
stable risk.
Assessment of equity
In order to assess the balance of malaria control fund-
ing globally, or funding equity, it is necessary to com-
pare each nation to a fixed standard, and analyze what
causes variation around this value. Therefore, the globe
was divided into three malarious regions, Africa+, Cen-
tral and South East Asia (CSE Asia) and the Americas
(see Additional file 1: for country listings) based upon
dominant vector species and other shared epidemio-
logical characteristics [22,38]. Within each region, re-
gional funds per capita-at-risk for the five year period
2006–10 were evaluated by dividing the total regional
funding over the five year period by the total population
at risk in the area. This average was defined as a theor-
etical ‘line of equity’ representing the amount that
would hypothetically have been disbursed to each coun-
try under the assumption of perfect per capita-at-risk
equity for each nation. Total disbursements and gov-
ernment funding within each country over the five-year
study period were compared to this equity line in order
to assess equity on the national scale. The per capita-at-
risk metric simplifies the distinct needs of each trans-
mission group identified, yet insufficient data on what
necessary funding is required by each category prevents
a more detailed analysis.
Results
Summary of global funding 2006–2010
Total funding for malaria control increased year-on-
year throughout the 2006–2010 period, from US$980
million in 2006 to US$2.55 billion in 2010 (Figure 1).
Funding from PMI has risen from US$65 million in its
first year of full funding (2006) to US$500 million across
17 countries in 2010, with similar figures for 2011 and
proposed for the FY2012 [39]. Likewise, the annual
disbursement from the Global Fund has increased dra-
matically from its inception, where the Round 1 com-
mitments in 2002 for malaria were US$68 million, to
releasing over US$1 billion in 2009 and close to that
amount again in 2010. This trend is further seen in the
amount donated by DAC nations, which displayed year-
on-year increases throughout the study period, with just
over US$400 million donated in 2010. UNICEF malariaPfPv Risk
Unstable Pv Risk No Pv Risk
All Stable Risk All Stable Risk
All Unstable Risk All Unstable Risk
Duffy Positives Unstable Risk None
Figure 1 Bar chart of amounts disbursed by different funding sources 2006–2010. The blue “Government” portion refers to the amounts
disbursed by national governments within their own country.
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and is now just around US$8 million, representing one
of the smaller funding streams investigated in this study.
There has been a decline in annual disbursements from
the World Bank’s Booster Scheme with most national
grants now being complete, or in their closing stages.
When considered together, external funding has nearly
quadrupled from US$535 million in 2006, to just under
US$2 billion in 2010. Over the same period, the total
domestic government funding across the globe has
remained relatively consistent, between US$500-600
million, but represents a declining proportion of total
global funding.
Some interesting findings in national-level funding
exist. Over the five-year period studied, eight malaria en-
demic countries had received no international support
(Table 2) and four others received negligible amounts
from the international community (under $50,000 cu-
mulative) (Table 2). These countries are all outside
Africa and are characterized by small populations at risk,
a predominance of P. vivax and above-average GDP per
capita.
Globally, there is an approximately linear relationship
between the national-level size of the population at risk
and total national-level funding (Figure 2A). Whilst
there is broad correspondence between the size ofTable 2 Countries where government funding represents the
Countries receiving no external support Belize, Costa Rica, Iraq, M
Countries receiving < $50000 over 2006-10 Argentina, Cape Verde, E





Uzbekistan, Venezuela, Vpopulation at risk in each country and the total amount
spent, the financing does not scale proportionately:
funding per capita-at-risk decreases as the total popula-
tion at risk increases, ranging from US$49 per capita-at-
risk in Suriname to as low as US$0.04 in China
(Figure 2B). This echoes data shown in the World Mal-
aria Report 2009, therefore suggesting that in spite of
the additional funding over the period 2007–2010, little
has changed in this regard [40].
As might be expected, comparison by country of the
relative contributions of government versus international
support revealed large differences in the degree of self-
reliance. Whilst most countries in which governmental
funding exceeded international support were those with
higher GDP per capita (Table 2), there were some not-
able exceptions that are discussed in more detail below.
Patterns of DAC disbursements remain strongly linked
to colonial legacies (Additional file 4). Portugal donated
100% of its contributions to former colonies, and over
90% of British disbursements were to Commonwealth
and former colonies. Over 80% of both Belgian and
French disbursements were similarly directed towards
their former territories. Australia shows an equivalent
bias with respect to its regional neighbours, with 99% of
support being directed towards the Asia-Pacific Region.
Interestingly, the additional international support of themajor funding stream
alaysia, Panama, Paraguay, Republic of Korea, Saudi Arabia, Turkey
l Salvador, Mexico
, Botswana, Brazil, Cape Verde, Colombia, Costa Rica, Ecuador, El Salvador,
, Iran, Iraq, Malaysia, Mexico, Namibia, Nicaragua, Pakistan, Panama,


























































Figure 2 Scatter plots of populations at risk and patterns of funding. Panel A shows total funding over the period 2006–2010 against size of
the population at risk of PfPv per country. Panel B shows annualized funding per capita against size of the population at risk of PfPv per country.
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ceiving PMI grants, predominantly in Sub-Saharan Africa,
strengthening their existing activities.
Table 3 summarizes the distribution of funding by glo-
bal region. Over 70% of all finance and 87% of all exter-
nal support for malaria control was spent in Africa. Asia
and the Americas received 17.93% and 8.74% of funding
respectively. These patterns are in contrast to global dis-
tributions of populations at risk. In absolute numbers,
CSE Asia accounts for 70% of global population at any
risk of malaria and 55% at stable risk. These differences
are further highlighted when comparing the regional
levels of equity. The Africa+ region averages US$1.60 per
person-at-risk per year, compared to US$0.93 in the
Americas and US$0.13 in CSE Asia. Even with the exclu-
sion of China and India, the per capita average in CSE
Asia only increases to US$0.33.
The Americas
Funding for malaria in the Americas region is dominated
by government funding (Figure 3). Of the 20 malaria en-
demic countries in the region, seven received less than
US$50,000 of international funding over the study
period. External support, when it has been supplied, is






CSE Asia 17.93% 11.47%
Americas 8.74% 1.64%in remote, high-risk communities of the Amazon Basin,
such as in Suriname, Guyana, Brazil and the Multi-
country Americas (Andean) Group (defined in Additional
file 3). Where these communities represent a significant
proportion of the total population at risk, above equit-
able levels of funding result; where not, the government
is expected to extend such support across the rest of the
country. Whilst Brazil, with the strongest economy in
the region, is capable of such an undertaking, Colombia,
Ecuador and Peru have not been able to do so, as shown
by their position below the line of equity for the Americas
region in Figure 3.
For several countries, the high levels of per capita-at-risk
funding correspond to the transition from low-endemic
control to elimination programmes. Costa Rica, Paraguay,
Mexico, Panama and Argentina all have relatively small
populations at risk, experience mainly unstable trans-
mission risk and their national governments have sup-
ported an elimination agenda, resulting in greater
than “equitable” funding.
Many of the countries that are struggling to maintain
per capita-at-risk funding parity are those that are cur-
rently more focused on controlling malaria rather than
elimination. Whilst in some cases it could be argued that








Figure 3 Bar chart of assessment of equitable funding in the Americas. Bars represent annualized per capita funding in each malaria
endemic country in the region relative to the line of equity, defined as the theoretical level if regional funding was perfectly distributed to
countries according to populations at risk. The divisions in the bar demonstrate the relative external and government contribution. For the
Americas, the line of equity is US$0.93 per capita per year. Countries labelled in red are in the process of moving from controlled low-endemic
malaria to elimination [53]. The y axis indicates by what factor the national per capita-at-risk funding differs from the line of equity.
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funding with that of Nicaragua – Additional file 1), this
is not the case for all, such as with Haiti and the Dominican
Republic. In the latter examples, we note that grants
were in place for these countries in 2011, which will
help to counter the apparent inequity. Haiti, for instance,
is set to receive US$18 million, greater than its cumula-
tive total of the previous five years.
Africa+
In Africa+, funding is dominated by international sup-
port (Figure 4). The majority of countries in the Africa +
region are control-focused, with strategies heavily
funded by external donors. It is therefore unsurprising
to see patterns of inequity driven by patterns in donor
assistance. Whilst the Global Fund is geographically
comprehensive in its funding strategy, providing fundinglargely in proportion to populations at risk, the disburse-
ment patterns of the DAC and PMI are more targeted
and thus introduce inequity in the continent-wide pat-
tern of funding. Of the 17 countries that received PMI
support by 2010, 14 have higher than equitable funding
on malaria when compared to their African neighbours
(Additional files 1 and 2). Similar trends are apparent
when DAC recipients are considered. The net result is
that, for countries outside of these funding streams (for
example, Cameroon, that relies primarily on the Global
Fund), funding per capita-at-risk is below the regional
average.
Some countries with proportionally large govern-
ment funding stand out, in terms of equitable levels of
funding, size of population at risk or levels of risk
compared to the rest of the region. Namibia and
South Africa have supported their goals of elimination
Figure 5 Bar chart of assessment of equitable funding in CSE Asia. Details as described for Figure 3. For CSE Asia, the line of equity is US$0.33.
Figure 4 Bar chart of assessment of equitable funding in Africa+. Details as described for Figure 3. For Africa+, the line of equity is US$1.60.
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similarly has higher than equitable funding, consistent
with the country’s relative wealth and small population
at risk, and is thus well placed to target elimination
through largely domestically financed programmes.
Swaziland and São Tomé and Príncipe, in contrast,
are supported in their elimination efforts predomin-
antly by the Global Fund and, given their small popu-
lations at risk, have higher than equitable funding. In
contrast, Botswana receives little international support
and is ineligible for the Global Fund ‘general pool’
(due to its classification as an Upper-Middle Income
country) meaning it cannot achieve parity with the
rest of the region despite above-average government
investment.
Central and South East Asia
The CSE Asia region is characterized by very diverse
levels of funding (Figure 5). There are strong ties be-
tween the ranking and the size of the population at risk,
echoing the trend of Figure 2B. Of the countries with
above-average levels of funding in the region, over two
thirds (12 of 17) are pursuing elimination. This is
achieved through either strong governmental commit-
ment, as in Turkey and Iran, or via concerted elimin-
ation programmes backed by the international
community, as with Vanuatu, the Solomon Islands and
the former Soviet states. That said, there are still some
nations which have commenced elimination pro-
grammes but are funding below equitable levels, such as
the Philippines or Vietnam. Levels of funding above the
equity line were found in those countries associated with
the emergence of artemisinin resistance, particularly
Cambodia [41]. Investment in resistance containment has
been led by the international community via targeted Glo-
bal Fund grants, and by the Thai government. Recent evi-
dence of resistance emergence in Myanmar [42] is
worrying however, particularly given the low levels of
funding there. The Global Fund has been a lone signifi-
cant international donor in the region but, as of 2011, the
PMI has become operational in the Greater Mekong sub-
region, with potentially important consequences for the
containment of artemisinin resistance [41].
Countries in the region with a higher per capita GDP
tended to have greater government funding relative to
donor assistance with two important exceptions: Indo-
nesia and China. Both countries receive substantial fund-
ing from the Global Fund, but provide comparatively
small government funding in support, meaning the
funding per capita-at-risk is surprisingly low. In contrast,
a high proportion of the funding in India and Pakistan
comes from internal resources relative to international
aid, yet these countries still only achieve minimal per
capita funding due to their significant population sizes.Discussion
This analysis indicates that external funding for malaria
was approximately US$2 billion in 2010 which, when
combined with national government funding, led to a
total of some US$2.5 billion spent that year on counter-
ing malaria globally. However, assessments have placed
annual funding needs for malaria control at between
four and six billion dollars [17,43]: a stark deficit per-
sists, therefore, between what is needed and what is
provided.
The distinction between equity and adequacy is critic-
ally important. It seems clear that few countries receive
adequate levels of funding but, even in the context of
this global inadequacy, there are marked discrepancies
when funding is compared to populations at risk. Com-
batting malaria must ultimately be considered as a global
endeavour and the challenge to the international com-
munity is to raise overall funding levels substantially
whilst seeking to address existing inequities. The inher-
ently interconnected nature of malaria epidemiology is
most clearly exemplified in elimination settings: the
threat of importation or potential for vector dispersal
from a neighbouring country will always represent a risk
[44]. Hence, ongoing adequate and equitable funding is
needed if the gains are to be sustained and progress to
date not undermined.
This analysis backs up the view that the trend for in-
creasing funding in the malaria sector is levelling off,
suggesting this deficit will remain [17]. In this context,
the onus lies on funders to maintain existing levels of
funding and recognize that these levels must be
increased if international targets in burden reduction
and elimination are to be realized. Crucially, however, it
can be seen that governments of malaria endemic coun-
tries across the GDP spectrum have committed smaller
proportions of their own national budgets than might be
expected when compared to regional neighbours. Indi-
vidual country-level assessments must be performed to
determine which sector is most culpable for any deficit
in the context of regional patterns of funding. In some
cases, increases in both internal and external funding are
required. There is no evidence to suggest a significant
displacement of government funding by international
support [45]; indeed the global level of government
funding remained relatively consistent between 2006 and
2010 despite large increases in donor assistance.
The observed inverse relationship between popula-
tion at risk and per capita-at-risk funding also pre-
sents a concern (Figure 2B) [40]. This relationship
implies that funding to those countries with the lar-
gest number of people at risk is not scaled suffi-
ciently. Whilst, in theory, economies of scale may
mean that protection of large populations becomes
less costly per capita, there is little evidence [46] to
Pigott et al. Malaria Journal 2012, 11:246 Page 9 of 11
http://www.malariajournal.com/content/11/1/246suggest this would compensate for the funding dis-
parities we observe. The marked decline observed in
per capita funding thus likely represents a systematic
under-funding in those countries with the largest
populations at risk.
The funding of disease control to minimize morbidity
and mortality burdens rightly dominates global funding
patterns. Africa, with the most intense transmission [22],
largest burden of mortality [3] and many of the world’s
poorest nations [33], receives close to 70% of all disbur-
sements. The region has also seen some of the greatest
successes against malaria, as well as some of the most
notable setbacks when funding has been withdrawn
[15,16]. In contrast, the CSE Asia region represents a
significant proportion of the global at-risk population,
but displays highly variable per capita-at-risk support
that is markedly inequitable in some cases. An important
aspect of these disparities is the role of P. vivax malaria
which arguably receives disproportionately little donor
funding for control, especially given a mounting body of
evidence suggesting its clinical importance has been
underestimated substantially [47-52]. When comparing
such regions it must be kept in mind that the per capita-
at-risk metric does not take into account the varying epi-
demiology that these regions represent. Doing so
requires a far greater assessment of the effectiveness of
different strategies in different scenarios, beyond the
scope of this study. Future investigations of this kind will
better enable future comparative assessments of equity
across the globe.
Of the countries targeting malaria elimination, over
two thirds (24 out of 35) have above-equitable levels of
funding. Due to small populations at risk, consideration
of absolute monies spent, as well as per capita amounts
in these cases is needed. Of the 35 nations identified as
pursuing malaria elimination [53], only 15 have an an-
nual per capita funding greater than US$2. This result,
combined with the total levels of funding in these coun-
tries, compares poorly to studies that have investigated
the necessary amounts of investment required for elim-
ination [54]. Many of those nations that are funding at
an appropriate level to make substantial progress to-
wards malaria elimination are either financing the oper-
ation themselves (such as Turkey or Saudi Arabia), or
are part of a concerted international elimination effort
(such as Solomon Islands and Vanuatu).
An interesting finding is that patterns of DAC dis-
bursements remain strongly linked to colonial leg-
acies, especially for Great Britain, Belgium, France
and Portugal – countries which are signatories to the
Paris Declaration and Accra Agenda for Action on
Aid Effectiveness that foster untied aid [55]. Similarly,
disbursements from USAID are primarily directed to
reinforcing PMI investments. In attempting to achieveadequacy of funding on malaria control in specific
countries, these have inadvertently become drivers of
uneven funding on a regional and global level.Conclusions
Global funding levels for malaria are in an increasingly
precarious state, and we must consolidate the gains that
have been facilitated by this financing over the last dec-
ade. To do so, commitments to existing programmes
that have proven successful must be reaffirmed, as well
as assessing whether existing patterns of funding are the
most appropriate. This analysis shows that, globally, in-
adequate levels of funding persist, and that there are
large inequalities, which vary in importance and ease of
resolution, whether through increased government sup-
port or international assistance. In some cases, inter-
national funding remains tied to colonial legacies rather
than disease burden. It is crucial that such imbalances
are addressed in attempting to secure adequate global
funding for malaria. The very large populations at risk in
CSE Asia suggest that this region should become more
prominent in discussions on future investment, but
increased funding should not be achieved through the
diversion of funds from other schemes. “Investing for
impact” represents a new principle for any future fund-
ing. Targeting the most at-risk populations and tailoring
disbursement of funds to a country’s needs, whilst still
framing funding decisions within the context of global
disease distribution, is key. Continued monitoring and
spatial assessments of national financial and disease sta-
tus will enable this and allow us to maximize the effect-
iveness of future funding.Additional files
Additional file 1: Funding for malaria by source.
Additional file 2: National Funding and Populations-at-Risk.
Additional file 3: Multi-Country Grants and Their Divisions.
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Abbreviations
CSE Asia: Central and South East Asia; DAC: Development Assistance
Committee; GDP: Gross Domestic Product; Global Fund: The Global Fund to
Fight AIDS, Tuberculosis and Malaria; MAP: Malaria Atlas Project;
PfPv: Combined P. falciparum and P. vivax; PMI: President’s Malaria Initiative;
UNICEF: United Nations Children’s Fund.
Competing interests
RA is a former Director of the Strategy, Performance and Evaluation cluster at
the Global Fund.
Authors’ contributions
RA, SIH and PWG conceived the analysis. DMP and PWG collated necessary
data and led the analysis. DMP and PWG wrote the first draft of the
manuscript. All authors contributed to refining the analysis and the final
version of the manuscript.
Pigott et al. Malaria Journal 2012, 11:246 Page 10 of 11
http://www.malariajournal.com/content/11/1/246Acknowledgements and funding
This work was funded by The Global Fund to Fight AIDS, Tubercolosis and
Malaria (#20013661). SIH is funded by a Senior Research Fellowship from the
Wellcome Trust (#095066), which also supports PWG. CLM is funded by a
Biomedical Resources Grant from the Wellcome Trust (#091835). We thank
Katherine Battle, Oliver Brady, Rosalind Howes and Jane Messina for suggesting
improvements and proof reading this document. This work forms part of the
output of the Malaria Atlas Project (MAP, http://www.map.ox.ac.uk), principally
funded by the Wellcome Trust, UK (http://www.wellcome.ac.uk). The paper
represents the views of the authors and is not the opinion or policy of the
Global Fund, unless otherwise stated.
Author details
1Department of Zoology, Spatial Ecology and Epidemiology Group,
University of Oxford, South Parks Road, Oxford, UK. 2Health Management
Group, Imperial College Business School, Imperial College London, London,
UK.
Received: 22 May 2012 Accepted: 13 July 2012
Published: 28 July 2012References
1. United Nations: United Nations Millenium Declaration. New York: United
Nations; http://www.un.org/millennium/declaration/ares552e.htm.
2. United Nations: Millennium Development Goals. New York: United Nations;
http://www.un.org/millenniumgoals/.
3. Murray CJL, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D,
Fullman N, Naghavi M, Lozano R, Lopez AD: Global malaria mortality
between 1980 and 2010: a systematic analysis. Lancet 2012, 379:413–431.
4. O'Meara WP, Mangeni JN, Steketee R, Greenwood B: Changes in the
burden of malaria in sub-Saharan Africa. Lancet Infect Dis 2010,
10:545–555.
5. Ceesay SJ, Casals-Pascual C, Erskine J, Anya SE, Duah NO, Fulford AJC, Sesay
SSS, Abubakar I, Dunyo S, Sey O, Palmer A, Fofana M, Corrah T, Bojang KA,
Whittle HC, Greenwood BM, Conway DJ: Changes in malaria indices
between 1999 and 2007 in The Gambia: a retrospective analysis. Lancet
2008, 372:1545–1554.
6. Steketee RW, Campbell CC: Impact of national malaria control scale-up
programmes in Africa: magnitude and attribution of effects. Malar J 2010,
9:299.
7. Meleigy M: The quest to be free of malaria. Bull World Health Organ 2007,
85:507–508.
8. WHO: Morocco certified malaria-free. Wkly Epidemiol Rec 2010, 85:235–236.
9. WHO: Turkmenistan certified malaria-free. Geneva: World Health Organization;
http://www.who.int/malaria/elimination/turkmenistancertifiedmalariafree/en/
index.html.
10. Akachi Y, Atun R: Effect of investment in malaria control on child
mortality in sub-Saharan Africa in 2002–2008. PLoS One 2011, 6:e21309.
11. Eisele TP, Larsen DA, Walker N, Cibulskis RE, Yukich JO, Zikusooka CM,
Steketee RW: Estimates of child deaths prevented from malaria
prevention scale-up in Africa 2001–2010. Malar J 2012, 11:93.
12. Leach-Kemon K, Chou DP, Schneider MT, Tardif A, Dieleman JL, Brooks BPC,
Hanlon M, Murray CJL: The global financial crisis has led to a slowdown
in growth of funding to improve health in many developing countries.
Health Aff 2012, 31:228–235.
13. Moszynski P: Global Fund suspends new projects until 2014 because of
lack of funding. BMJ 2011, 343:d7755.
14. Garrett L: Global health hits crisis point. Nature 2012, 482:7.
15. Smith DL, Cohen JM, Moonen B, Tatem AJ, Sabot OJ, Ali A, Mugheiry SM:
Solving the Sisyphean problem of malaria in Zanzibar. Science 2011,
332:1384–1385.
16. Cohen JM, Smith DL, Cotter C, Ward A, Yamey G, Sabot OJ, Moonen B:
Malaria resurgence: a systematic review and assessment of its causes.
Malar J 2012, 11:122.
17. Newman RD: Relegating malaria resurgences to history. Malar J 2012,
11:123.
18. Kazatchkine M: A message to staff, partners and friends from the Executive Director.
Geneva: The Global Fund to Fight AIDS, Tuberculosis and Malaria; 2012. http://
www.theglobalfund.org/en/mediacenter/announcements/2012-01-24_
A_message_to_staff_partners_and_friends_from_the_Executive_Director/.19. Global Fund: The Global Fund strategy 2012–2016: Investing for impact.
Geneva: The Global Fund to Fight AIDS, Tuberculosis and Malaria; 2011.
20. Snow RW, Guerra CA, Mutheu JJ, Hay SI: International funding for malaria
control in relation to populations at risk of stable Plasmodium falciparum
transmission. PLoS Med 2008, 5:1068–1078.
21. Snow RW, Okiro EA, Gething PW, Atun R, Hay SI: Equity and adequacy of
international donor assistance for global malaria control:an analysis of
populations at risk and external funding commitments. Lancet 2010,
376:1409–1416.
22. Gething PW, Patil AP, Smith DL, Guerra CA, Elyazar IRF, Johnston GL, Tatem
AJ, Hay SI: A new world malaria map: Plasmodium falciparum endemicity
in 2010. Malar J 2011, 10:378.
23. Gething PW, Elyazar IRF, Moyes CL, Smith DL, Battle KE, Guerra CA, Patil AP,
Tatem AJ, Howes RE, Myers MF, George DB, Horby P, Wertheim HFL, Price
RN, Mueller I, Baird JK, Hay SI: A long neglected world malaria map:
Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis 2012, in press.
24. MAP: Malaria Atlas Project. Oxford: University of Oxford; www.map.ox.ac.uk.
25. Hay SI, Snow RW: The Malaria Atlas Project: developing global maps of
malaria risk. PLoS Med 2006, 3:e473.
26. Global Fund: Grant data. Geneva: The Global Fund to Fight AIDS,
Tuberculosis and Malaria; http://portfolio.theglobalfund.org/en/
DataDownloads/Index.
27. OECD: Creditor reporting system. Paris: Organisation For Economic Co-
operation and Development; http://stats.oecd.org/index.aspx?
DataSetCode=CRS1.
28. PMI: Fifth annual report to Congress. Washington: The President's Malaria
Initiative; http://www.pmi.gov/resources/reports/pmi_annual_report11.pdf.
29. PMI: Malaria operational plans for fiscal year 2011. Washington: The
President's Malaria Intiative; http://www.pmi.gov/countries/mops/fy11/index.
html.
30. Global Fund: Country portfolios. Geneva: The Global Fund to Fight AIDS,
Tuberculosis and Malaria; http://portfolio.theglobalfund.org/en/Home/Index.




32. WHO: World Malaria Report 2011. Geneva: World Health Organization; 2011.
33. World B: GDP data. Washington: World Bank; http://data.worldbank.org/
indicator/NY.GDP.MKTP.CD/countries/1W?display=default.
34. CIA: The CIA factbook. Washington: Central Intelligence Agency; https://
www.cia.gov/library/publications/the-world-factbook/.
35. Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperley WH,
Kabaria CW, Tatem AJ, Manh BH, Elyazar IRF, Baird JK, Snow RW, Hay SI: The
international limits and population at risk of Plasmodium vivax
transmission in 2009. PLoS Negl Trop Dis 2010, 4.
36. Langhi DM, Bordin JO: Duffy blood group and malaria. Hematology 2006,
11:389–398.
37. Howes RE, Patil AP, Piel FB, Nyangiri OA, Kabaria CW, Gething PW,
Zimmerman PA, Barnadas C, Beall CM, Gebremedhin A, Menard D, Williams
TN, Weatherall DJ, Hay SI: The global distribution of the Duffy blood
group. Nat Commun 2011, 2:266.
38. Hay SI, Guerra CA, Gething PW, Patil AP, Tatem AJ, Noor AM, Kabaria CW,
Manh BH, Elyazar IRF, Brooker S, Smith DL, Moyeed RA, Snow RW: A world
malaria map: Plasmodium falciparum endemicity in 2007. PLoS Med 2009,
6:e1000048.
39. PMI: Malaria operational plans for fiscal year 2012. Washington: The
President's Malaria Initiative; http://www.fightingmalaria.gov/countries/
mops/fy12/index.html.
40. WHO: World Malaria Report 2009. Geneva: World Health Organization; 2009.
41. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F,
Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K,
Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NPJ, Lindegardh
N, Socheat D, White NJ: Artemisinin resistance in Plasmodium falciparum
malaria. N Engl J Med 2009, 361:455–467.
42. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, Ler Moo
C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day NP, White NJ,
Anderson TJ, Nosten F: Emergence of artemisinin-resistant malaria on the
western border of Thailand: a longitudinal study. Lancet 2012, 379:
1960–1966.
43. Kiszewski A, Johns B, Schapira A, Delacollette C, Crowell V, Tan-Torres T,
Ameneshewa B, Teklehaimanot A, Nafo-Traore F: Estimated global
Pigott et al. Malaria Journal 2012, 11:246 Page 11 of 11
http://www.malariajournal.com/content/11/1/246resources needed to attain international malaria control goals. Bull World
Health Organ 2007, 85:623–630.
44. Le Menach A, Tatem AJ, Cohen JM, Hay SI, Randell H, Patil AP, Smith DL:
Travel risk, malaria importation and malaria transmission in Zanzibar.
Sci Rep 2011, 1:93.
45. Batniji R, Bendavid E: Does development assistance for health really
displace government health spending? Reassessing the evidence. PLoS
Med 2012, 9:e1001214.
46. Global Fund: Price and quality reporting tool. Geneva: The Global Fund to
Fight AIDS, Tuberculosis and Malaria; http://www.theglobalfund.org/en/
procurement/pqr/.
47. Baird JK: Neglect of Plasmodium vivax malaria. Trends Parasitol 2007,
23:533–539.
48. Price RN, Douglas NM, Anstey NM: New developments in Plasmodium
vivax malaria: severe disease and the rise of chloroquine resistance. Curr
Opin Infect Dis 2009, 22:430–435.
49. Carlton JM, Sina BJ, Adams JH: Why is Plasmodium vivax a neglected
tropical disease? PLoS Negl Trop Dis 2011, 5:e1160.
50. Bousema T, Drakeley C: Epidemiology and infectivity of Plasmodium
falciparum and Plasmodium vivax gametocytes in relation to malaria
control and elimination. Clin Microbiol Rev 2011, 24:377–410.
51. Genton B, D'Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, Mueller I:
Plasmodium vivax and mixed infections are associated with severe
malaria in children: A prospective cohort study from Papua New Guinea.
PLoS Med 2008, 5:881–889.
52. Anstey NM, Russell B, Yeo TW, Price RN: The pathophysiology of vivax
malaria. Trends Parasitol 2009, 25:220–227.
53. The Global Health Group and the Malaria Atlas Project: Atlas of malaria-
eliminating countries, 2011. San Fransisco: The Global Health Group, Global
Health Services, University of California; 2011.
54. Sabot O, Cohen JM, Hsiang MS, Kahn JG, Basu S, Tang LH, Zheng B, Gao Q,
Zou LD, Tatarsky A, Aboobakar S, Usas J, Barrett S, Cohen JL, Jamison DT,
Feachem RGA: Malaria elimination 4: Costs and financial feasibility of
malaria elimination. Lancet 2010, 376:1604–1615.
55. OECD: Paris declaration and Accra agenda for action. Paris: Organisation For
Economic Co-operation and Development; http://www.oecd.org/
document/18/0,3746,en_2649_3236398_35401554_1_1_1_1,00.html.
doi:10.1186/1475-2875-11-246
Cite this article as: Pigott et al.: Funding for malaria control 2006–2010:
A comprehensive global assessment. Malaria Journal 2012 11:246.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
